Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.

Clinicaltrial registered28 Oct 2026

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.

28 Oct 2026: Trial registered · Phase 1 Study to Evaluate RG002C0106 Injection in Healthy Participants. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
28 Oct 2026
Title
Phase 1 Study to Evaluate RG002C0106 Injection in Healthy Participants
Conditions
Safety Issues
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Austria
Country
Austria
Reference
NCT07902245
Location
Austria
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Austria

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.